Wednesday, March 19, 2014

Horizon Pharma to Acquire Vidara in $660 Million Reverse Merger

 Horizon Pharma has agreed to acquire Vidara Therapeutics International through a reverse merger for stock and cash valued at about $660 million.  

As per the agreement, Vidara will combine with Horizon Pharma Inc. with approximately 74 percent of Horizon Pharma ordinary shares to be exchanged for Horizon Pharma's common shares, with Horizon surviving the merger. Here is more on the reverse merger.